desferal 0 5 g
novartis pharma stein ag, stein, suiza. wasserburger arzneimittel werk gmbh, bayern, alemania. fabricante alternativo - deferoxamina - polvo liofilizado para inyección im, iv y sc - 500 mg
flumikan 100mg/5ml solucion oral
novartis biosciences peru s.a. - droguerÍa - acetilcisteina; - solucion oral - por dosis 1.00 dosis - - acetilcisteÍna
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - antígenos de superficie del virus de la gripe (hemaglutinina y neuraminidasa) de la cepa a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacunas - inmunización activa contra el subtipo h5n1 del virus influenza a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptina, metformin hidrocloruro - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 y 5. 1 para datos disponibles sobre diferentes combinaciones).
cosentyx 150 mg/ml solución inyectable
novartis pharma a.g. suiza - secukinumab (ain457)----150,0 mg/ml - soluciÓn inyectable - cada mililitro contiene: secukinumab (ain457)----150,0 mg
myfortic 360 mg comprimidos gastrorresistentes
novartis pharma ag suiza - micofenolato sódico ???????????????? 384.8 mg equivalente a ácido micofenólico???????? 360.0 mg - comprimidos gastrorresistentes - cada comprimido gastrorresistente contiene: núcleo del comprimido: principio activo: micofenolato sódico ???????????????? 384.8 mg equivalente a ácido micofenólico???????? 360.0 mg
myfortic 180 mg comprimidos gastrorresistentes
novartis pharma ag suiza - micofenolato sódico ???????????????? 192.4 mg equivalente a ácido micofenólico???????? 180.0 mg - comprimidos gastrorresistentes - cada comprimido gastrorresiste contiene: núcleo del comprimido: principio activo: micofenolato sódico ???????????????? 192.4 mg equivalente a ácido micofenólico???????? 180.0 mg
cosentyx (secukinumab) 150 mg/ml solucion inyectable en jeringa prellenada
novartis de venezuela s.a. - secukinumab -
cosentyx (secukinumab) 150mg polvo liofilizado para solucion inyectabl
novartis de venezuela, s.a. - secukinumab -
signifor lar 20 mg polvo para suspension inyectable
novartis de venezuela, s.a. - pasireotida - polvo para suspension inyectable - 20 mg